Unió Europea - italià - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - lopinavir, ritonavir - infezioni da hiv - antivirals for systemic use, protease inhibitors - kaletra è indicato in combinazione con altri medicinali antiretrovirali per il trattamento del virus dell'immunodeficienza umana (hiv-1) infettata adulti, adolescenti e bambini a partire da 14 giorni di età. la scelta di kaletra per il trattamento inibitore della proteasi con esperienza infetti da hiv-1 in pazienti dovrebbe essere basato su test di resistenza virale individuale e la storia di trattamento dei pazienti.

Unió Europea - italià - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ritonavir - infezioni da hiv - antivirali per uso sistemico - ritonavir è indicato in combinazione con altri agenti antiretrovirali per il trattamento di pazienti con infezione da hiv-1 (adulti e bambini di due anni di età e oltre).

Unió Europea - italià - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infezioni da hiv - antivirali per uso sistemico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - fluconazolum - capsule - fluconazolum 50 mg, colore.: e 131, excipiens per la capsula. - antifungini - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - fluconazolum - capsule - fluconazolum 150 mg, colore.: e 131, excipiens per la capsula. - antifungini - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - fluconazolum - capsule - fluconazolum 200 mg, colore.: e 127, e 132, excipiens pro capsula. - antifungini - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - fluconazolum - polvere per la preparazione di una sospensione - fluconazolum 50 mg, sono, conserv.: e 211, excipiens di polvere corrisp. sospensione reconstituta 5 ml. - antifungini - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - fluconazolum - polvere per la preparazione di una sospensione - fluconazolum 200 mg, sono, conserv.: e 211, excipiens di polvere corrisp. sospensione reconstituta 5 ml. - antifungini - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - lopinavirum, ritonavirum - sirup - lopinavirum 80 mg, ritonavirum 20 mg, macrogolglyceroli hydroxystearas 10.2 mg, aqua purificata, natrii chloridum, natrii citras dihydricus, saccharinum natricum, acesulfamum kalicum, acidum citricum, ethanolum anhydricum 356.3 mg, propylenglycolum 152.7 mg, levomentholum, povidonum k 29-32, glycerolum, sirupus saccharidae corresp. fructosum 101.2 mg et glucosum 59.1 mg, ammonii glycyrrhizas, menthae piperitae aetheroleum, aromatica (vanille) cum glucosum et natrii benzoas, aromatica (zuckerwatte), ad solutionem pro 1 ml corresp. ethanolum 42.4 % v/v et natrium 2.41 mg. - le infezioni da hiv - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - lopinavirum, ritonavirum - compresse rivestite con film - lopinavirum 200 mg, ritonavirum 50 mg, copovidonum k 28, sorbitani lauras, silica colloidalis anhydrica, natrii stearylis fumaras, Überzug: hypromellosum, macrogolum 400, hydroxypropylcellulosum, talcum, macrogolum 3350, polysorbatum 80, silica colloidalis anhydrica, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium 724 µg. - le infezioni da hiv - synthetika